文献速递白血病造血干细胞移植与细胞治疗

单倍体与全相合无关供者移植治疗缓解期AML的前瞻性对比研究

Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study.
PubMed 文献 · Am J Hematol · 2020-11-24

该前瞻性研究纳入110例缓解期急性髓系白血病患者,比较单倍体移植与HLA全相合无关供者移植的结局。中位随访47个月,两组总生存、无病生存、复发、非复发死亡及无GVHD无复发生存均无显著差异,证实单倍体移植非劣于全相合无关供者移植,并验证WT1定量作为MRD标志物的作用。

要点

  • 单倍体移植总生存非劣于全相合无关供者移植,两组差异无统计学意义。
  • 单倍体移植EBV或CMV感染更常见,T细胞重建延迟。
  • 移植前WT1表达独立预测复发及更差生存。

核心结论

  • 在缓解期AML中,单倍体移植对总生存的非劣效性得到证实,与全相合无关供者移植相比主要结局无显著差异。
  • 移植前WT1定量作为MRD标志物可独立预测复发和不良生存。

研究设计与样本

  • 前瞻性对比研究,纳入110例缓解期AML患者,比较单倍体移植与HLA全相合无关供者移植。
  • 单倍体移植采用独特的减低毒性预处理方案,全相合无关供者移植多采用清髓性方案。
  • 中位随访47个月,另对110例未入组患者进行单独分析以验证一致性。

主要发现

  • EBV或CMV感染在单倍体移植中更常见,且单倍体移植T细胞重建延迟。
  • 多因素分析显示移植前WT1表达独立预测复发并导致更差生存。

临床怎么用

  • 缓解期AML患者缺乏全相合无关供者时,单倍体移植可作为非劣效的替代选择。
  • 单倍体移植后需加强EBV和CMV感染监测及T细胞免疫重建评估。
  • 移植前应检测WT1表达以评估复发风险并指导分层管理。

局限性

  • 样本量较小(n=110),可能影响部分终点的统计效能。
  • 两组预处理方案强度不同(减低毒性 vs 多清髓性),可能混杂结局比较。
  • 单倍体移植T细胞重建延迟及EBV/CMV感染更常见的机制未进一步阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite comparable outcomes of haploidentical transplants (Haplo-HSCT) with HLA-matched unrelated transplants (MUD-HSCT) in retrospective comparisons, few studies have prospectively compared Haplo-HSCT with MUD-HSCT in AML. Here, we prospectively compared the outcomes of Haplo-HSCT with MUD-HSCT for AML in remission (n = 110) to prove non-inferiority of overall survival in Haplo-HSCT. Both groups were well balanced in factors related to biological features of AML and measurable residual disease (MRD) status by Wilms' tumor gene 1 (WT1) assay. A unique, reduced-toxicity preparative regimen was used for Haplo-HSCT, whereas mostly-myeloablative regimen was for MUD-HSCT. Both groups showed similar patterns of neutrophil and platelet recovery, whereas delayed T-cell reconstitution in Haplo-HSCT was found compared with MUD-HSCT. No significant differences were found in acute or chronic graft-vs-host-disease (GVHD) and post-transplant infectious events with an exception of EBV or CMV infection, which occurred more frequently in Haplo-HSCT. After a median follow-up of 47 months, no significant differences in overall survival (65% vs 54%, P = .146), disease-free survival (67% vs 53%, P = .142), relapse (20% vs 21%, P = .858), non-relapse mortality (14% vs 26%, P = .103), or GVHD-free/relapse-free survival (54% vs 41%, P = .138) were observed for Haplo-HSCT vs MUD-HSCT. In multivariate analysis, WT1 expression before transplantation independently predicted relapse, resulting in inferior survival. Separate analysis of unenrolled patients (n = 110) who were excluded or refused to participate in this study showed consistent results with enrolled patients. This prospective study demonstrated the non-inferiority of Haplo-HSCT to MUD-HSCT for AML in remission, and validated the role of WT1 quantification as an MRD marker (ClinicalTrial.gov identifier: NCT01751997).

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Cho BS, Min GJ, Park S, et al. Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study. Am J Hematol. 2020. PMID: 32905642. doi:10.1002/ajh.25993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。